Skip to main content

Pharmacokinetics of micafungin in patients with severe burn injuries

Introduction

Micafungin (MCFG), an echinocandin antifungal agent, exhibits more potent antifungal activity against a broad spectrum of clinically important Candida and Aspergillus species [1]. However, there are few pharmacokinetic data of antifungal agents for burned patients, and determination of the dosage for these populations requiring initially a large quantity of fluid therapy can trouble burn surgeons and intensivists. The purpose of this study is to obtain the pharmacokinetic data for MCFG in severe burned patients.

Methods

In six patients with severe burn injuries within 14 days after injuries (19 to 82 years old, 36 to 85% TBSA), we measured the plasma concentration of MCFG by high-performance liquid chromatography [2] after drip infusion of MCFG, at 200 to 300 mg/day over a 1-hour period. Blood samples were collected at the end of the initial administration of MCFG (peak value after initial administration; A point), immediately before the second dosing (trough value after initial administration; B), at the end of the fourth dosing (steady-state peak value; C), and immediately before the fifth dosing (steady-state trough value; D). The control value of plasma concentration of MCFG assumed the pharmacokinetics value obtained from healthy volunteers.

Results

The plasma concentration of MCFG at the A point were 10.1 to 24.2 μg/ml, 1.8 to 6.1 μg/ml at B, 11.3 to 27.9 μg/ml at C, and 2.3 to 7.9 μg/ml at D. In both peak and trough values there was a good correlation between the plasma concentration of MCFG and the dose of MCFG per kilogram body weight the same as cases of healthy volunteers (Figure 1).

Figure 1
figure1

Correlation between the plasma concentration of MCFG and the dose of MCFG (mg/kg).

Conclusions

These results suggest that MCFG can be administered safely to burned patients without adjusting the dose.

References

  1. 1.

    Aikawa N, et al.: J Infect Chemother. 2009, 15: 219-227. 10.1007/s10156-009-0689-5

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Yamato Y, et al.: Jpn J Chemother. 2002,50(Suppl 1):80-87.

    CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to J Sasaki.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Sasaki, J., Kishino, S., Hori, S. et al. Pharmacokinetics of micafungin in patients with severe burn injuries. Crit Care 15, P241 (2011). https://doi.org/10.1186/cc9661

Download citation

Keywords

  • Plasma Concentration
  • Healthy Volunteer
  • Emergency Medicine
  • Broad Spectrum
  • Antifungal Activity